Skip to main content
. 2021 Mar 3;2021:6676609. doi: 10.1155/2021/6676609

Table 2.

Grouping of in vivo primary study.

HA MSC VEGF
Group 1—8 implants 500 mg 3 × 106 10 ng release/day
Group 2—8 implants 500 mg 3 × 106 100 ng release/day
Group 3—8 implants 500 mg 3 × 106 500 ng release/day
Group 4—8 implants 500 mg Allograft